Vext Science (FRA:VV5) Change In Receivables: €1.13 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:VV5 Vext Science Inc FRA:VV5
53 GF Score
Price €0.16
GF Value €0.16
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Vext Science Change In Receivables?

Vext Science FRA:VV5 -1.86% 53 Change In Receivables is €1.13 Mil as of Jun. 2026. GuruFocus rates FRA:VV5 with a GF Score™ of 53/100 and a GF Value™ of €0.16 (Fairly Valued). The stock has 4 warning signs investors should review.

Vext Science's change in receivables for the quarter that ended in Jun. 2026 was €-0.15 Mil. It means Vext Science's Accounts Receivable increased by €0.15 Mil from Mar. 2026 to Jun. 2026 .

Vext Science's change in receivables for the fiscal year that ended in Dec. 2025 was €-0.02 Mil. It means Vext Science's Accounts Receivable increased by €0.02 Mil from Dec. 2024 to Dec. 2025 .

Vext Science's Accounts Receivable for the quarter that ended in Jun. 2026 was €0.47 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Vext Science's Days Sales Outstanding for the three months ended in Jun. 2026 was 4.08.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Vext Science's liquidation value for the three months ended in Jun. 2026 was €-45.42 Mil.

Vext Science  (FRA:VV5) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Vext Science's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0.47/10.523*91
=4.08

2. In Ben Graham's calculation of liquidation value, Vext Science's accounts receivable are only considered to be worth 75% of book value:

Vext Science's liquidation value for the quarter that ended in Jun. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=3.936-54.661+0.75 * 0.47+0.5 * 9.898
=-45.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vext Science Change In Receivables Related Terms

Vext Science Change In Receivables Historical Data

* Premium members only.

The historical data trend for Vext Science's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vext Science Change In Receivables Chart

Vext Science Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Receivables
Get a 7-Day Free Trial Premium Member Only -4.13 -1.17 1.32 0.11 -0.02

Vext Science Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.07 -0.20 0.73 0.74 -0.15
FRA:VV5
53GF Score
Vext Science Inc FRA:VV5
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vext Science Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.13 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of €1.13 Mil mean?
Vext Science (FRA:VV5) has a Change In Receivables of €1.13 Mil as of Jun. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Vext Science and its competitors.
Is Vext Science's Change In Receivables too high?
Vext Science's current Change In Receivables is €1.13 Mil. Overall, Vext Science has a GF Score™ of 53/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vext Science's Change In Receivables compare to ZTS?
Vext Science's Change In Receivables of €1.13 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Drug Manufacturers company?
A good Change In Receivables depends on the Drug Manufacturers industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Vext Science and its competitors. Vext Science's current Change In Receivables is €1.13 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vext Science stock overvalued right now?
Based on GuruFocus' analysis, Vext Science (FRA:VV5) is currently considered Fairly Valued. The stock's GF Value™ is €0.16, compared to a current price of €0.16 — trading 1.3% below its estimated fair value. The current Change In Receivables is €1.13 Mil. Vext Science's overall GF Score™ is 53/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Vext Science (FRA:VV5), the current Change In Receivables is €1.13 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vext Science (FRA:VV5) Overvalued in 2026?

Based on GuruFocus' analysis, Vext Science stock appears to be undervalued. The current stock price of €0.16 is trading 1.3% below its estimated GF Value™ of €0.16. GuruFocus considers Vext Science to be Fairly Valued.

Key valuation signals for FRA:VV5:

  • Change In Receivables: €1.13 Mil
  • GF Value™: €0.16 vs. price of €0.16 (1.3% below fair value)
  • GF Score™: 53/100 with 4 warning signs

No single metric tells the full story. See the FRA:VV5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vext Science Business Description

Other Exchanges VEXTF:USAVEXT:Canada
Address 4152 N. 39th Avenue, Admin, Phoenix, AZ, USA, 85019
Vext Science Inc engages in the full spectrum of the cannabis product lifecycle, from development and manufacturing to distribution. Its brands include Herbal Wellness, Appalachian Pharm, Revibe, Prism, Vapen, and Firebrand. In Arizona and Ohio, the dispensaries operate under the Herbal Wellness Center brand, while in Ohio the cultivation and manufacturing operations are licensed and branded as Appalachian Pharms Cultivation and Appalachian Pharm Processing. The Company operates through a single operating segment engaged in the cultivation, manufacturing, distribution, and sale of cannabis within the United States. All revenues are generated in the United States.
53GF Score

Get the complete analysis for FRA:VV5

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.16
Price
€0.16
GF Value